EN
登录

赛诺菲新一代狂犬病疫苗VaxRabeo在欧盟获批,适用于所有年龄段人群

Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages

赛诺菲 等信源发布 2026-11-19 14:10

可切换为仅中文


Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages

赛诺菲的新一代狂犬病疫苗VaxRabeo在欧盟获批,适用于所有年龄段人群

Paris, November 19, 2026.

巴黎,2026年11月19日。

Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) against rabies for all age groups. This is the first marketing authorisation approval for VaxRabeo and follows the positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use on September 17, 2026..

赛诺菲今日宣布,欧盟委员会已批准VaxRabeo(狂犬病病毒灭活Wistar株)用于所有年龄组的暴露前预防(PrEP)和暴露后预防(PEP)。这是VaxRabeo获得的首个上市许可批准,此前欧洲药品管理局人用医药产品委员会已于2026年9月17日通过积极意见。

VaxRabeo is manufactured using state of the art Vero-cell technology. It is formulated to minimize the risk of allergic reactions and has a longer shelf life than current Sanofi rabies vaccines with an improved thermostability.

VaxRabeo 采用先进的 Vero 细胞技术生产。其配方旨在最大限度地降低过敏反应风险,且相较于赛诺菲现有的狂犬病疫苗,具有更长的保质期和更好的热稳定性。

Rabies is a viral zoonotic disease present in 150 countries, causing approximately 59,000 deaths worldwide annually, according to World Health Organization (WHO) estimates. No treatment exists and it is only preventable by vaccines (in combination with immunoglobulins in post-exposure prophylaxis); once clinical symptoms appear, the disease is almost always fatal.

根据世界卫生组织(WHO)的估计,狂犬病是一种存在于150个国家的病毒性人畜共患疾病,每年在全球导致约59,000人死亡。目前尚无治疗方法,仅能通过疫苗进行预防(在暴露后预防中需与免疫球蛋白联合使用);一旦出现临床症状,该病几乎总是致命的。

It is transmitted primarily through the saliva of infected animals, most commonly via dog bites, and remains a significant global public health challenge despite being entirely vaccine preventable. According to the WHO, approximately 29 million people receive post-exposure vaccination each year. .

该病主要通过受感染动物的唾液传播,最常见的是通过狗咬伤传播。尽管完全可以通过疫苗预防,但它仍然是一个重大的全球公共卫生挑战。据世界卫生组织称,每年约有2900万人接受暴露后疫苗接种。

'Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time. This first approval of VaxRabeo is a proud milestone for Sanofi and reflects our commitment to rabies protection, built on five decades of expertise and innovation. With VaxRabeo, we are bringing a next-generation rabies vaccine to healthcare systems and patients,' .

“必须不惜一切代价防止狂犬病致死;只要及时接种疫苗,狂犬病是完全可以预防的。VaxRabeo 的首次获批是赛诺菲引以为豪的里程碑,体现了我们基于五十年专业积累与创新,在狂犬病防护领域的坚定承诺。通过 VaxRabeo,我们将为医疗卫生系统和患者带来新一代狂犬病疫苗。”

said

说

Thomas Triomphe

托马斯·特里昂夫

, Head of Vaccines, Sanofi.

,赛诺菲疫苗部门负责人。

The EU approval is supported by a comprehensive clinical programme comparing VaxRabeo with Sanofi’s current standard of care vaccines (Verorab and Imovax Rabies) in both PrEP and PEP settings, across all age groups and WHO recommended schedules. VaxRabeo showed comparable protective antibody levels in PrEP, a similar immunogenicity profile in PEP, and high boostability of the booster dose given 12 or 24-36 months after PrEP.

欧盟的批准基于一项全面的临床试验计划,该计划在暴露前预防(PrEP)和暴露后预防(PEP)场景下,涵盖所有年龄组及世界卫生组织推荐的接种程序,将VaxRabeo与赛诺菲现有的标准护理疫苗(Verorab和Imovax Rabies)进行了比较。VaxRabeo在暴露前预防中显示出相当的 protective 抗体水平,在暴露后预防中表现出相似的免疫原性特征,并且在暴露前预防后12个月或24-36个月给予的加强剂量具有高_boostability_(加强免疫应答能力)。

VaxRabeo showed a safety profile in line with existing vaccines and no significant safety concerns..

VaxRabeo 表现出与现有疫苗一致的安全性特征,且无重大安全性担忧。

About rabies

关于狂犬病

Rabies is a viral zoonotic disease that affects the central nervous system. Transmission occurs predominantly through the saliva of infected animals, with dogs responsible for most human cases, typically through bites, scratches, and contact with broken skin. Other mammals, including cats, bats, foxes, raccoons, skunks, jackals, and mongooses can also transmit the virus to humans.

狂犬病是一种影响中枢神经系统的病毒性人畜共患病。传播主要通过感染动物的唾液进行,狗是导致大多数人类病例的主要原因,通常通过咬伤、抓伤和接触破损皮肤传播。其他哺乳动物,包括猫、蝙蝠、狐狸、浣熊、臭鼬、豺狼和獴等,也可以将病毒传播给人类。

Children bear a disproportionate burden: 40% of people bitten by suspect rabid animals are under 15 years of age. Despite being entirely vaccine preventable rabies continues to cause preventable deaths, particularly in Asia and Africa. For travellers visiting endemic regions, potential rabies exposure occurs in approximately 0.4% of travellers per month of stay, making pre-travel vaccination an important consideration..

儿童承受着不成比例的负担:在被疑似狂犬病动物咬伤的人群中,40%为15岁以下儿童。尽管狂犬病完全可以通过疫苗预防,但它仍在继续导致本可避免的死亡,尤其是在亚洲和非洲地区。对于前往流行地区的旅行者而言,每停留一个月,约有0.4%的旅行者可能暴露于狂犬病风险中,这使得出行前接种疫苗成为一项重要的考量。

About VaxRabeo

关于 VaxRabeo

VaxRabeo (rabies virus inactivated strain Wistar) is produced using Vero cell technology and shares the same viral strain as Verorab and Imovax Rabies vaccines, which have demonstrated proven safety and efficacy over more than five decades. It is indicated for pre-exposure and post-exposure prophylaxis against rabies for all age groups, and offers flexible vaccination schedules, including reduced WHO-recommended 2-dose PrEP, and 4-dose PEP for unvaccinated individuals, administered with or without rabies immunoglobulin.

VaxRabeo(狂犬病病毒灭活株Wistar)采用Vero细胞技术生产,与Verorab和Imovax狂犬病疫苗使用相同的病毒株,这两种疫苗在五十多年的应用中已证明其安全性和有效性。该疫苗适用于所有年龄组的暴露前和暴露后狂犬病预防,并提供灵活的接种方案,包括世界卫生组织推荐的简化2剂次暴露前预防(PrEP)方案,以及针对未接种者的4剂次暴露后预防(PEP)方案,可单独接种或联合狂犬病免疫球蛋白使用。

In PrEP studies, two-dose and three-dose regimens of VaxRabeo achieved protective antibody levels comparable to those of Verorab and Imovax Rabies in both adults and children. Booster doses administered 12 or 24–36 months after the last PrEP dose demonstrated high boostability, supporting the lasting immunogenicity of VaxRabeo.

在暴露前预防(PrEP)研究中,VaxRabeo 的两剂和三剂接种方案在成人和儿童中均达到了与 Verorab 和 Imovax Rabies 相当的 protective antibody levels(保护性抗体水平)。在最后一剂 PrEP 后 12 个月或 24–36 个月给予的加强剂量显示出良好的加强免疫效果,支持 VaxRabeo 具有持久的免疫原性。

In PEP studies, VaxRabeo demonstrated a similar immunogenicity profile to current Sanofi SoC vaccines when administered with or without rabies immunoglobulins, with 100% of participants achieving protective antibody levels intramuscularly. Across all studies, VaxRabeo showed an acceptable safety profile like existing vaccines, was well tolerated, and no significant safety concerns were identified when administered alone or with rabies immunoglobulins..

在暴露后预防(PEP)研究中,无论是否联合使用狂犬病免疫球蛋白,VaxRabeo 均展现出与赛诺菲现有标准治疗(SoC)疫苗相似的免疫原性特征,所有受试者经肌肉注射后均达到了保护性抗体水平。在所有研究中,VaxRabeo 表现出与现有疫苗相当的可接受安全性特征,耐受性良好,且无论是单独给药还是与狂犬病免疫球蛋白联合给药,均未发现重大安全性问题。

VaxRabeo has a 60-month (five years) shelf-life and maintains stability at temperatures up to 27°C for 96 hours before reconstitution.

VaxRabeo的保质期为60个月(五年),在复溶前可在高达27°C的温度下保持稳定96小时。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

赛诺菲是一家以研发为驱动、人工智能赋能的生物制药公司,致力于改善人类生活并实现强劲增长。我们凭借对免疫系统的深刻理解,研发用于治疗和保护全球数百万人的药物与疫苗,并通过创新的產品管线惠及更多人群。我们的团队秉持一个宗旨:追寻科学奇迹以改善人类生活;这激励我们应对当今最紧迫的医疗、环境和社会挑战,推动进步,为员工和我们服务的社区创造积极影响。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

赛诺菲在泛欧交易所(股票代码:SAN)和纳斯达克(股票代码:SNY)上市。

Media Relations

媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

sandrine.guendoul@sanofi.com

Evan Berland

埃文·伯兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

evan.berland@sanofi.com

evan.berland@sanofi.com

Léo Le Bourhis

莱奥·勒布尔希斯

| +33 6 75 06 43 81 |

| +33 6 75 06 43 81 |

leo.lebourhis@sanofi.com

leo.lebourhis@sanofi.com

Victor Rouault

维克多·鲁奥

| +1 617 356 4751 |

| +1 617 356 4751 |

victor.rouault@sanofi.com

victor.rouault@sanofi.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

+1 516 521 2929

timothy.gilbert@sanofi.com

timothy.gilbert@sanofi.com

Léa Ubaldi

莱娅·乌巴尔迪

| +33 6 30 19 66 46 |

| +33 6 30 19 66 46 |

lea.ubaldi@sanofi.com

lea.ubaldi@sanofi.com

Ekaterina Pesheva

叶卡捷琳娜·佩舍娃

| +1 410 926 6780 |

| +1 410 926 6780 |

ekaterina.pesheva@sanofi.com

ekaterina.pesheva@sanofi.com

Laura Romby

劳拉·朗比

| +33 6 74 16 74 29 |

| +33 6 74 16 74 29 |

laura.romby@sanofi.com

laura.romby@sanofi.com

Investor Relations

投资者关系

Thomas Kudsk Larsen

托马斯·库德克·拉森

| +44 7545 513 693 |

| +44 7545 513 693 |

thomas.larsen@sanofi.com

thomas.larsen@sanofi.com

Alizé Kaisserian

阿利泽·凯瑟里安

| +33 6 47 04 12 11 |

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

alize.kaisserian@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

keita.browne@sanofi.com

keita.browne@sanofi.com

Nathalie Pham

娜塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

nathalie.pham@sanofi.com

Nina Goworek

妮娜·戈沃雷克

| +1 908 569 7086 |

| +1 908 569 7086 |

nina.goworek@sanofi.com

nina.goworek@sanofi.com

Thibaud Châtelet

蒂博·沙泰莱

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

yun.li3@sanofi.com

Sanofi forward-looking statements

赛诺菲前瞻性陈述

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product.

本新闻稿包含根据适用证券法律(包括经修订的1995年《私人证券诉讼改革法》)所定义的“前瞻性陈述”。前瞻性陈述是指非历史事实的陈述。这些陈述包括对产品营销及其他潜力的预测和估计,以及关于产品未来潜在事件和收入的相关假设。

Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” 'attempt,' “target,” “project,” 'strategy,' 'strive,' 'desire,' “predict,” “forecast,” “ambition,” “guideline,” 'seek,' “should,” “will,” 'goal,' or the negative of these and similar expressions are intended to identify forward-looking statements.

“预期”、“ anticipate ”、“相信”、“打算”、“估计”、“计划”、“能够”、“考虑”、“可能”、“旨在”、“可以”、“或许”、“潜在”、“目标”、“尝试”、“指标”、“预测”、“规划”、“战略”、“努力”、“期望”、“预言”、“预报”、“雄心”、“指导方针”、“寻求”、“应该”、“将会”、“目的”等词语,以及这些词语的否定形式或类似表达,均用于识别前瞻性陈述。

Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

尽管赛诺菲管理层认为此类前瞻性陈述中所反映的预期是合理的,但提醒投资者注意,前瞻性信息和陈述受各种风险和不确定性的影响,其中许多难以预测且通常超出赛诺菲的控制范围,可能导致实际结果和发展与前瞻性信息和陈述中明示、暗示或预测的内容存在重大差异。

These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug.

这些风险、不确定性和假设包括但不限于:意外的监管行动或延误,或一般的政府监管,这可能影响产品的可获得性或商业潜力;产品可能无法在商业上取得成功;监管机构关于是否以及何时批准候选产品的决定;美国要求降低药价的政治压力。

All trademarks mentioned in this press release are the property of the Sanofi group.

本新闻稿中提及的所有商标均为赛诺菲集团的财产。

Attachment

附件

Press_Release

新闻稿

Share

分享